527 related articles for article (PubMed ID: 34140953)
21. Recent advances in understanding myelofibrosis and essential thrombocythemia.
Vainchenker W; Constantinescu SN; Plo I
F1000Res; 2016; 5():. PubMed ID: 27134742
[TBL] [Abstract][Full Text] [Related]
22. Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition.
Kong T; Laranjeira ABA; Collins TB; De Togni ES; Wong AJ; Fulbright MC; Ruzinova M; Celik H; Challen GA; Fisher DAC; Oh ST
Blood Adv; 2022 Jan; 6(2):611-623. PubMed ID: 34644371
[TBL] [Abstract][Full Text] [Related]
23. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
24. The Role of Inflammation and Inflammasome in Myeloproliferative Disease.
Longhitano L; Li Volti G; Giallongo C; Spampinato M; Barbagallo I; Di Rosa M; Romano A; Avola R; Tibullo D; Palumbo GA
J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32707883
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
26. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.
Kaushansky K; Zhan H
Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351
[TBL] [Abstract][Full Text] [Related]
27. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.
Verma T; Papadantonakis N; Peker Barclift D; Zhang L
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339265
[TBL] [Abstract][Full Text] [Related]
28. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.
Stein BL; Williams DM; Rogers O; Isaacs MA; Spivak JL; Moliterno AR
Exp Hematol; 2011 Jan; 39(1):95-101. PubMed ID: 20888389
[TBL] [Abstract][Full Text] [Related]
29. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
[TBL] [Abstract][Full Text] [Related]
30. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
31. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
[TBL] [Abstract][Full Text] [Related]
32. [What's new in myeloproliferative neoplasia?].
Schmidt S; Wolf D
Dtsch Med Wochenschr; 2022 Mar; 147(6):306-311. PubMed ID: 35291035
[TBL] [Abstract][Full Text] [Related]
33. Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis.
Sangle N; Cook J; Perkins S; Teman CJ; Bahler D; Hickman K; Wilson A; Prchal J; Salama ME
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):663-8. PubMed ID: 24897074
[TBL] [Abstract][Full Text] [Related]
34. VEGF Regulation of Angiogenic Factors via Inflammatory Signaling in Myeloproliferative Neoplasms.
Subotički T; Mitrović Ajtić O; Živković E; Diklić M; Đikić D; Tošić M; Beleslin-Čokić B; Dragojević T; Gotić M; Santibanez JF; Čokić V
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206393
[TBL] [Abstract][Full Text] [Related]
35. [Myeloproliferative disorders].
Binder D; Fehr J
Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
[TBL] [Abstract][Full Text] [Related]
36. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling.
Fisher DAC; Miner CA; Engle EK; Hu H; Collins TB; Zhou A; Allen MJ; Malkova ON; Oh ST
Leukemia; 2019 Aug; 33(8):1978-1995. PubMed ID: 30718771
[TBL] [Abstract][Full Text] [Related]
37. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
[TBL] [Abstract][Full Text] [Related]
38. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.
Sangiorgio VFI; Nam A; Chen Z; Orazi A; Tam W
Leuk Res; 2021 Jan; 100():106495. PubMed ID: 33360878
[TBL] [Abstract][Full Text] [Related]
39. Canonical Wnt/β-Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis.
Lucijanic M; Livun A; Tomasovic-Loncaric C; Stoos-Veic T; Pejsa V; Jaksic O; Prka Z; Kusec R
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):523-526. PubMed ID: 27381374
[TBL] [Abstract][Full Text] [Related]
40. A case of a primary myelofibrosis with progression and related literature review of progression phase genetics.
Chen D; Fuda F; Weinberg O
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():78-81. PubMed ID: 34288445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
